RNS Number : 2969X
Tristel PLC
01 September 2025
 

TRISTEL plc

("Tristel" or the "Company")

 

Confirmation of CFO Appointment

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, confirms the appointment of Anna Wasyl as Chief Financial Officer ("CFO") of Tristel, effective from today.

 

As previously announced in July 2025, Anna joins the Company replacing Liz Dixon who left the business on 30 June 2025, having been with the Group since 2007. Anna brings extensive experience from her previous roles across different sectors including medical devices, robotics, and industrial automation. She has over 20 years of experience across publicly listed and venture-backed companies and joins from CMR Surgical, the Cambridge-based global surgical robotics business, where she served as Chief Commercial Partnerships and Operations Officer, having previously held the role of Group CFO. 

 

A person in a blue suit AI-generated content may be incorrect.

 

Anna Wasyl, Chief Financial Officer of Tristel plc

 

Matt Sassone, CEO of Tristel plc, said: "Anna has joined at an exciting time for Tristel plc. We welcome Anna to the Tristel team and look forward to updating the market on the Company's progress at the preliminary results in October."

 

For further information please contact:

Tristel plc

Via Walbrook PR

Matt Sassone, Chief Executive Officer

www.investors.tristel.com

Anna Wasyl, Chief Financial Officer




Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus / Lianne Applegarth / Anna Dunphy 

Mob: 07980 541 893/ 07584 391 303/ 07876 741 001  



Cavendish Capital Markets Ltd

Tel: 020 7220 0500

Geoff Nash / Callum Davidson/Trisyia Jamaludin (Corporate Finance)


Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)


 

A blue and purple sign with white text AI-generated content may be incorrect.

 

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the Tristel brand, and under the Cache brand provides products for sporicidal surface disinfection, a more sustainable alternative to commonly used pre-wetted plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets annual revenue growth of between 10% and 15% and an EBITDA margin of at least 25% and the business is profitable, with no debt and has a progressive dividend policy.

 

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit: https://tristel.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAPKCBDNBKDAFB